Quanterix Corporation (QTRX)Healthcare | Medical Devices | Billerica, United States | NasdaqGM
3.88 USD
After hours: 3.90 +0.02 (0.515%) ⇧ (July 13, 2026, 7:17 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 5:57 a.m. EDT
The investment case for Quanterix is currently broken by a severe deterioration in profitability and a multi-year price collapse. While the company boasts impressive revenue growth of 20%, the bottom line is hemorrhaging cash, with operating margins at -59% and free cash flow in the negative millions. The market has punished this relentlessly, sending the share price down over 60% from its peak seven years ago. Although the stock trades at a discount to book value, this is a classic value trap where the balance sheet is eroding rather than providing a safety margin. The lack of any dividend history confirms the capital is being burned on operations rather than returned to shareholders. On the short end, the heavy put writing suggests traders are betting on continued weakness, making this a dangerous environment for new entries. The statistical forecast offers no directional clarity, which is typical for such volatile, distressed small-cap biotech names. Until the path to profitability is clearly defined and sustained, the risk-reward profile remains skewed heavily against the buyer. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.133908 |
| MSTL | 0.137893 |
| AutoTheta | 0.259572 |
| AutoARIMA | 0.267909 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 36% |
| H-stat | 1.16 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.234 |
| Excess Kurtosis | -0.28 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 12.524 |
| Revenue per Share | 3.243 |
| Market Cap | 182,771,200 |
| Forward P/E | -2.85 |
| Beta | 1.04 |
| Profit Margins | -71.86% |
| Website | https://www.quanterix.com |
As of July 11, 2026, 5:57 a.m. EDT: Speculators are overwhelmingly positioning for downside protection. Put open interest significantly exceeds call open interest across all expirations, with deep out-of-the-money puts holding the highest volume relative to strikes. This indicates a strong consensus among retail traders that further declines are likely, despite the stock testing resistance levels recently.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.3586777 |
| Address1 | Building 1 |
| Address2 | 900 Middlesex Turnpike |
| All Time High | 92.57 |
| All Time Low | 2.395 |
| Ask | 4.9 |
| Ask Size | 2 |
| Audit Risk | 10 |
| Average Analyst Rating | 3.0 - Hold |
| Average Daily Volume10 Day | 954,070 |
| Average Daily Volume3 Month | 1,226,690 |
| Average Volume | 1,226,690 |
| Average Volume10Days | 954,070 |
| Beta | 1.038 |
| Bid | 2.89 |
| Bid Size | 2 |
| Board Risk | 6 |
| Book Value | 5.995 |
| City | Billerica |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.88 |
| Current Ratio | 3.722 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 4.04 |
| Day Low | 3.81 |
| Debt To Equity | 12.524 |
| Display Name | Quanterix |
| Earnings Call Timestamp End | 1,778,099,400 |
| Earnings Call Timestamp Start | 1,778,099,400 |
| Earnings Timestamp | 1,778,097,600 |
| Earnings Timestamp End | 1,786,046,400 |
| Earnings Timestamp Start | 1,786,046,400 |
| Ebitda | -63,673,000 |
| Ebitda Margins | -0.43919 |
| Enterprise To Ebitda | -1.866 |
| Enterprise To Revenue | 0.82 |
| Enterprise Value | 118,842,208 |
| Eps Current Year | -1.23 |
| Eps Forward | -1.36 |
| Eps Trailing Twelve Months | -2.35 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 3.3029 |
| Fifty Day Average Change | 0.57710004 |
| Fifty Day Average Change Percent | 0.17472525 |
| Fifty Two Week Change Percent | -35.867767 |
| Fifty Two Week High | 8.77 |
| Fifty Two Week High Change | -4.8900003 |
| Fifty Two Week High Change Percent | -0.5575827 |
| Fifty Two Week Low | 2.395 |
| Fifty Two Week Low Change | 1.4850001 |
| Fifty Two Week Low Change Percent | 0.6200418 |
| Fifty Two Week Range | 2.395 - 8.77 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,512,657,000,000 |
| Float Shares | 38,459,207 |
| Forward Eps | -1.36 |
| Forward P E | -2.8529413 |
| Free Cashflow | -21,983,500 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 450 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.45308 |
| Gross Profits | 65,687,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.06302 |
| Held Percent Institutions | 0.85260004 |
| Implied Shares Outstanding | 47,105,981 |
| Industry | Medical Devices |
| Industry Disp | Medical Devices |
| Industry Key | medical-devices |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Quanterix Corporation, a life sciences company in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, the company offers contract research and clinical laboratory testing services, including research and clinical trial testing, and lucent diagnostic services. The company primarily operates in the areas of neurology, oncology and immunology, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and sales force and distributors. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts. |
| Long Name | Quanterix Corporation |
| Market | us_market |
| Market Cap | 182,771,200 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_47689694 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -104,187,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 182,771,206 |
| Number Of Analyst Opinions | 3 |
| Open | 3.89 |
| Operating Cashflow | -81,455,000 |
| Operating Margins | -0.59116 |
| Overall Risk | 6 |
| Payout Ratio | 0.0 |
| Phone | 617 301 9400 |
| Post Market Change | 0.01999998 |
| Post Market Change Percent | 0.5154634 |
| Post Market Price | 3.9 |
| Post Market Time | 1,783,984,667 |
| Previous Close | 3.88 |
| Price Eps Current Year | -3.1544716 |
| Price Hint | 4 |
| Price To Book | 0.647206 |
| Price To Sales Trailing12 Months | 1.2606735 |
| Profit Margins | -0.71863997 |
| Quick Ratio | 2.536 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | hold |
| Recommendation Mean | 3.0 |
| Region | US |
| Regular Market Change | 0.0 |
| Regular Market Change Percent | 0.0 |
| Regular Market Day High | 4.04 |
| Regular Market Day Low | 3.81 |
| Regular Market Day Range | 3.81 - 4.04 |
| Regular Market Open | 3.89 |
| Regular Market Previous Close | 3.88 |
| Regular Market Price | 3.88 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 286,903 |
| Return On Assets | -0.13387 |
| Return On Equity | -0.34814 |
| Revenue Growth | 0.201 |
| Revenue Per Share | 3.243 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 3 |
| Shares Outstanding | 47,105,981 |
| Shares Percent Shares Out | 0.0919 |
| Shares Short | 4,327,379 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 5,057,385 |
| Short Name | Quanterix Corporation |
| Short Percent Of Float | 0.1035 |
| Short Ratio | 3.37 |
| Source Interval | 15 |
| State | MA |
| Symbol | QTRX |
| Target High Price | 5.0 |
| Target Low Price | 4.0 |
| Target Mean Price | 4.33333 |
| Target Median Price | 4.0 |
| Total Cash | 99,265,000 |
| Total Cash Per Share | 2.107 |
| Total Debt | 35,336,000 |
| Total Revenue | 144,979,008 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.35 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 5.0762 |
| Two Hundred Day Average Change | -1.1961999 |
| Two Hundred Day Average Change Percent | -0.23564869 |
| Type Disp | Equity |
| Volume | 286,903 |
| Website | https://www.quanterix.com |
| Zip | 1,821 |